Document:

Exhibit 10.20

 

FIRST AMENDMENT TO LICENSE
AGREEMENT BETWEEN LANKENAU

INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS

CORPORATION DATED JULY 7, 2005

 

This First Amendment to the License Agreement (“First Amendment”) between Lankenau Institute for Medical
Research (“LIMR”) and NewLink Genetics
Corporation (“NewLink” or “Company”)
is made on this May 22 day of May, 2006 (“Effective
Date”).

 

WHEREAS, NewLink entered into a certain License Agreement
with LIMR dated July 7, 2005 (“Original Agreement”)
pursuant to which NewLink was granted a license for certain intellectual
property owned by LIMR;

 

WHEREAS, LIMR owns technology developed by its
employee-investigator, George Prendergast, PhD, that is related to the
technology licensed by LIMR to NewLink under the Original Agreement; and

 

WHEREAS, Pursuant to and in accordance with Section 2.a.
of the Original Agreement LIMR must notify NewLink of and provide NewLink with
a “first look” at any additional research findings that directly result from
the use of the technology described in Patent Applications [*];
and

 

WHEREAS, LIMR has provided NewLink with such notice and
information regarding [*] (“Additional Technology”) and NewLink would like to license
the Additional Technology.

 

NOW THEREFORE, in consideration of the promises and mutual
covenants herein contained, and for the other good and valuable consideration,
the receipt and sufficiency of which are acknowledged, and intending to be
legally bound, the parties agree as follows:

 

AGREEMENT

 

1.                                      Incorporation
of Preamble and Recitals. 
The Preamble and Recitals set forth above are incorporated into this
First Amendment as if set forth in full.

 

2.                                      Definitions.  All capitalized terms used
in this First Amendment and not defined herein shall have the meaning given to
them in the Original Agreement.  From and
after the Effective Date hereof, the term “Agreement” as used herein and in the
Original Agreement shall mean the Original Agreement as amended by this First
Amendment.

 

3.                                      Section 1(e).  Section 1(e) of
the Original Agreement is amended and restated in its entirety as follows:

 

1

 

“LIMR Technology.  “LIMR Technology” shall mean the technology
described in Patent Applications [*] (“Originally Licensed Technology”) and the technology
described in Patent Application [*] (“Additional Technology;” the Originally Licensed Technology
and the Additional Technology shall be referred to together as the “LIMR Technology.”) as well as in all future patent
applications derived from the above mentioned applications such as
international, divisional, amended, continuations and/or continuations-in-part
patent applications.”

 

4.                                      Section 1(g).  Section 1(g) of
the Original Agreement is amended by changing the period at the end of said Section to
a comma and adding thereafter the following: 
“and [*].”

 

5.                                      Section 2(a).  The first sentence of Section 2(a) of
the Original Agreement is amended and restated as follows:

 

“LIMR hereby grants to Company an exclusive,
world-wide, royalty-bearing license (“License”) under
the LIMR Technology and the Patent Rights for LIMR Technology described in
Patent Applications [*] and the
Patent Rights to make, have made, use and/or sell Licensed Product in the field
of human and animal therapeutics and diagnostics (the “Field”):

 

The
last sentence of Section 2(a) is also amended by changing the period
at the end thereof to a comma and adding thereafter the following:  “and [*].”

 

6.                                      Section 7.  Section 7 of the
Original Agreement is amended and restated in its entirety as follows:

 

“a.                                 Initial Fee.  Upon the execution of this Agreement, which
occurred as of July 7, 2005, NewLink shall pay to LIMR a License
Initiation Fee of [*], the
receipt of which LIMR hereby acknowledges.

 

b.                                      Annual
Fee.  NewLink shall pay LIMR an annual
license fee on account of the Original Technology of [*]
which shall be due and payable on July 7 of each year during the term of
this Agreement.  NewLink shall also pay
LIMR an annual license on account of the Additional Technology of [*]

 

2

 

which shall be due and payable on each anniversary
of the date of the Amendment to License Agreement.”

 

7.                                      License
Initiation Fee for Additional Technology.  Upon execution of this First
Amendment by NewLink, NewLink shall pay to LIMR a license initiation fee of [*].

 

8.                                      Entire
Agreement.  The Original
Agreement, as amended by this First Amendment shall constitute the entire
agreement between the parties with respect to the subject matter hereof.  Except as expressly amended hereby, the
Original Agreement is hereby ratified and confirmed.  In the event of a conflict between the terms
of the Original Agreement and the terms of this First Amendment, the terms of
this First Amendment shall prevail.

 

IN WITNESS WHEREOF, and intending to be
legally bound hereby, the parties have caused this Amendment to be executed by
their duly authorized representatives.

 

	
  Lankenau Institute for Medical
  Research

  	
   

  	
  NewLink Genetics Corporation

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Edward L. Jones, Jr.

  	
   

  	
  By:

  	
  /s/ Nicholas Vahanian

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Chairman

  	
   

  	
  Title:

  	
  Chief Medical and Operations Officer

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
   

  	
   

  	
  Date:

  	
  5/22/2006

  

 

3Exhibit 10.21

 

SECOND AMENDMENT TO LICENSE
AGREEMENT BETWEEN LANKENAU

INSTITUTE FOR MEDICAL RESEARCH AND NEWLINK GENETICS

CORPORATION DATED JULY 7, 2005

 

This
Second Amendment to the License Agreement
(“Second Amendment”) between Lankenau
Institute for Medical Research (“LIMR”) and
NewLink Genetics Corporation (“NewLink” or “Company”) is made on this 11th day of September, 2007 (“Effective Date”).

 

WHEREAS, NewLink entered into a certain License Agreement
with LIMR dated July 7, 2005 pursuant to which NewLink was granted a
license for certain intellectual property owned by LIMR, which was amended by a
certain First Amendment to the Original Agreement with LIMR dated May 22,
2006 (as amended, the “Original Agreement”)
pursuant to which NewLink was granted a license for certain Additional
Technology referred to as [*]; and

 

WHEREAS, LIMR owns technology developed by its
employee-investigator, George Prendergast, PhD, that is related to the
technology licensed by LIMR to NewLink under the Original Agreement; and

 

WHEREAS, Pursuant to and in accordance with Section 2.a.
of the Original Agreement LIMR must notify NewLink of and provide NewLink with
a “first look” at any additional research findings that directly result from
the use of the technology described in Patent Applications [*];
and

 

WHEREAS, LIMR has provided NewLink with such notice and
information regarding [*] (“Subsequent Additional Technology”) and NewLink would like to
license the Subsequent Additional Technology.

 

NOW THEREFORE, in consideration of the promises and mutual
covenants herein contained, and for the other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties
hereby agree as follows:

 

AGREEMENT

 

1.                                      Incorporation
of Preamble and Recitals.  The Preamble and Recitals
set forth above are incorporated into this Second Amendment as if set forth in
full.

 

2.                                      Definitions.  All capitalized terms used
in this Second Amendment and not defined herein shall have the meaning given to
them in the Original

 

1

 

Agreement. 
From and after the Effective Date hereof, the term “Agreement” as used
herein and in the Original Agreement shall mean the Original Agreement as
amended by this Second Amendment.

 

3.                                      Section 1(e).  Section 1(e) of
the Original Agreement is amended and restated in its entirety as follows:

 

“LIMR Technology.  “LIMR Technology” shall mean the technology
described in Patent Applications [*] (“Originally Licensed Technology”), the technology described
in Patent Application [*] (“Additional Technology”), and the technology described in
Patent Application [*] (“Subsequent Additional Technology”; the Originally Licensed
Technology, the Additional Technology, and the Subsequent Additional Technology
shall be referred to together as the “LIMR Technology.”)
as well as in all future patent applications derived from the above mentioned
applications such as international, divisional, amended, continuations and/or
continuations-in-part patent applications.”

 

4.                                      Section 1(g).  Section 1(g) of
the Original Agreement is amended by changing the period at the end of said Section to
a comma and adding thereafter the following: 
“and [*]”

 

5.                                      Section 2(a).  The first sentence of Section 2(a) of
the Original Agreement is amended and restated as follows:

 

“LIMR hereby grants to Company an exclusive,
world-wide, royalty-bearing license (“License”) under
the LIMR Technology and the Patent Rights for LIMR Technology described in
Patent Applications [*] and the
Patent Rights to make, have made, use and/or sell the Licensed Product in the
field of human and animal therapeutics and diagnostics (the “Field”).

 

The last sentence of Section 2(a) is also
amended by changing the period at the end thereof to a comma and adding thereafter
the following:  “and [*]”

 

6.                                      Section 7.  Section 7 of the
Original Agreement is amended and restated in its entirety as follows:

 

“a.  Initial
Fee.  Upon execution of this Agreement,
which occurred as of July 7, 2005, NewLink shall pay to LIMR a License
Initiation Fee of

 

2

 

[*], the receipt of which LIMR hereby acknowledges.

 

b.  Annual
Fee.  NewLink shall pay LIMR an annual
license fee on account of the Original Technology of [*] which
shall be due and payable on July 7 of each year during the term of this
Agreement.  NewLink shall also pay LIMR
an annual license fee on account of the Additional Technology of [*] which shall be due and payable on May 22 of each
year during the term of this Agreement and an annual license fee on account of
the Subsequent Additional Technology of [*] which shall
be due and payable on each anniversary of the date of the Second Amendment to
the License Agreement.”

 

7.                                      License
Initiation Fee for Subsequent Additional Technology.  Upon execution of this
Second Amendment by NewLink, NewLink shall pay to LIMR a license initiation fee
of [*].

 

8.                                      Entire
Agreement.  The Original
Agreement as amended by this Second Amendment shall constitute the entire
agreement between the parties with respect to the subject matter hereof.  Except as expressly amended hereby, the
Original Agreement is hereby ratified and confirmed.  In the event of a conflict between the terms
of the Original Agreement and the terms of this Second Amendment, the terms of
this Second Amendment shall prevail.

 

IN WITNESS WHEREOF, and intending to be
legally bound hereby, the parties have caused this Amendment to be executed by
their duly authorized representatives.

 

	
  Lankenau Institute for Medical
  Research

  	
   

  	
  NewLink Genetics Corporation

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Edward L. Jones, Jr.

  	
   

  	
  By:

  	
  /s/ Nicholas Vahanian

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
  Chairman

  	
   

  	
  Title:

  	
  Chief Medical and Operations Officer

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  9/18/07

  	
   

  	
  Date:

  	
  9/11/07

  

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]